CEACAM5 and neoplasm: During the course of pembrolizumab therapy, serum tumor markers carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA21-1) demonstrated a mild decline (Supplementary Figure S2) (Supplementary Figure S3).